Online inquiry

IVTScrip™ mRNA-Anti-EPHA3, KB-004(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ9925MR)

This product GTTS-WQ9925MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets EPHA3 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_005233.6
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2042
UniProt ID P29320
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-EPHA3, KB-004(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ9925MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ15276MR IVTScrip™ mRNA-Anti-EGFR, Theraloc(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA Theraloc
GTTS-WQ4620MR IVTScrip™ mRNA-Anti-LAG3, BMS-986016(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BMS-986016
GTTS-WQ5217MR IVTScrip™ mRNA-Anti-CD22, CAT-8015(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA CAT-8015
GTTS-WQ5263MR IVTScrip™ mRNA-Anti-S, CB-6(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA CB-6
GTTS-WQ10963MR IVTScrip™ mRNA-Anti-IL17A&IL17F, MCAF-5352A(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MCAF-5352A
GTTS-WQ9749MR IVTScrip™ mRNA-Anti-TFRC, JR-141(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA JR-141
GTTS-WQ2558MR IVTScrip™ mRNA-Anti-IGF1R, AMG 479(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA AMG 479
GTTS-WQ12333MR IVTScrip™ mRNA-Anti-TIGIT, MTIG-7192-A(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA MTIG-7192-A
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW